A new medical device has been developed that promises to revolutionize the way peritoneoscopy is performed. OUI Medical has completed a cadaver study using its peritoneoscope, a portable handheld scope with an integrated camera, screen, processor, battery, and biopsy forceps. The Institutional Review Board has cleared the scope for a clinical study, which is expected to begin in April.
Peritoneoscopy is a minimally invasive procedure that is used to examine the inside of the abdomen. It is typically performed under general anesthesia in a hospital or a surgical center. However, with Oui Medical’s peritoneoscope, the procedure can now be performed at the point of care under local anesthesia or local anesthesia with sedation.
The peritoneoscope is a disposable device, which eliminates the need for reprocessing and reduces the risk associated with cross-contamination. Additionally, the low acquisition cost of the device makes it an affordable option for medical facilities of all sizes.
“We are thrilled to announce the completion of our cadaver study and clearance from the Institutional Review Board for a clinical study,” said Dr Adarsh M Patil MD consultant minimal access surgeon. “Our goal with this device is to make peritoneoscopy more accessible, less invasive, and more affordable for patients and medical facilities alike. We are excited to move forward with our clinical study and continue to improve the future of medical care.”
For more information about the Peritoneoscope, please contact Dr Adarsh Patil: ap@oui-medical.com
Vital has raised $24.7 million in a Series B funding round. The digital health company focused on improving the patient experience. It uses AI to facilitate communication between clinicians, health systems and patients during emergency department and inpatient visits. The new funding will support software development and expansion efforts. Transformation Capital led the round, with support from Threshold Ventures, strategic health system investors and Vital CEO / Mint.com creator Aaron Patzer. To date Vital has raised more than $40 million.
To read more, click here.
Cognito Therapeutics, an innovator in neuromodulation which recently received the breakthrough device designation from the FDA to start pivotal studies for the treatment of Alzheimer’s disease, has raised a $73 million Series B financing round.
FoundersX Ventures led the round, with participation from its existing investors. They include: New investors Alzheimer’s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and WS Investment Company (Wilson Sonsini’s venture arm) joined the round. The Series B funding brings the total amount raised since inception to $93 million.
The fresh capital will be used to advance Cognito’s neuromodulation device, which uses gamma frequency light and sound stimulation to treat Alzheimer’s Disease. In a prior Phase 2 clinical trial, Cognito’s device showed a significant slowing in functional and cognitive decline in the treatment group, as well as a significant decline in brain atrophy over a six-month period, according to a press release. Cognito is currently enrolling patients in its pivotal clinical trial HOPE for Alzheimer’s Disease, across approximately 50 clinical centers in the United States with a target enrollment of 500 patients.
To read more, click here.
Reveal HealthTech, a technology company seeking to remedy the staff recruitment and retention challenges in healthcare, has raised $4 million from W Health Ventures — marking the early stage investor’s first health tech investment.
Reveal HealthTech provides engineering, clinical, and strategic support services to healthcare. It plans to use the new funding to develop its service suite, grow its customer base, and expand talent acquisition, training, and development efforts, according to a press release.
To read more, click here.
Picture: Feodora Chiosea, Getty Images
